With $1.2B NASH deal behind them, Nimbus raises $65M for I/O, other R&D
You might remember Nimbus for the massive NASH deal it inked with Gilead a couple years back — earning a remarkable $400 million upfront. The company’s bread and butter has been teaming up with heavyweights like Gilead, Celgene, and Genentech to take its promising roster of drugs through development. But now, Nimbus is stepping out with plans to push forward its own internal set of programs — and the company’s backers just put up $65 million to finance the work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.